US FDA advisers to consider if new COVID shots should target JN.1 Variant ???
Shares of Novavax soared 11% in morning trade, after the documents were released.
London: Advisers to the U.S. Food and Drug Administration will vote whether recommend that COVID-19 vaccines for 2024-25 should target the JN.1 variant, the most dominant this year, documents filed on Monday showed.
Shares of Novavax soared 11 per cent in morning trade, after the documents were released. The company had said last month it would The company had said last month it would only be able to offer a COVID vaccine in the United States this autumn if regulators accept the shot it started manufacturing to target the JN.1 variant.
What's Your Reaction?
